One-Time gene injection aims to rescue sight in rare childhood blindness

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years (adult participants) or 12-17 years (adolescent participants) at the time of consent/assent. * Provide written informed consent and/or assent prior to any study procedures. * Willing to adhere to the clinical protocol and follow directions of the Investigator regarding post-surgery restrictions. * Are a good candidate for surgery, per the Investigator's judgment. * Have LCA with autosomal-recessive RDH12 mutation(s), confirmed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. Historic testing, up to 15 years prior to date of consent, may be considered. * Clinical diagnosis of LCA with RDH12 mutation(s), in the judgment of the Investigator. * BCVA 20/200 (1.0 logarithm of the minimum angle of resolution \[logMAR\]) or worse for the sentinel adult in each cohort; BCVA 20/40 (0.5 logMAR) or worse for all subsequent participants in each cohort. Exclusion Criteria: * Women of childbearing potential (WOCBP) who are pregnant, lactating, and/or unwilling to use effective contraception from Screening through 1 year after IMP administration. * Men who are unwilling to use effective contraception from Screening through 180 days after IMP administration. * Have an ocular infection, a pre-existing eye condition, or a complicating systemic disease that could preclude the planned surgery or any future ocular surgery. This includes individuals who are immunocompromised and/or on continuous systemic immunosuppressive therapy. * Have a past or current condition that may preclude participation in the study, interfere with outcome measure testing or test results, or otherwise make the potential participant unsuitable for the study. * Have previously received gene therapy of any kind. * In either eye, have undergone intraocular surgery within 90 days prior to planned IMP administration or have active inflammation at Screening resulting from prior ocular surgery. * Have used any investigational device or investigational drug within 90 days (or 5 half-lives of the drug, whichever is longer) prior to planned IMP administration or intend to participate in another drug or device study during the same period as the current study. * Have received or plan to receive a vaccination within 6 weeks prior to or 6 weeks after IMP administration. Note: For the influenza vaccine, the exclusionary period is shorter: 2 weeks prior to and 5 weeks after IMP administration (i.e., during steroid treatment). * Have received anticoagulant therapy within 2 weeks prior to planned IMP administration. * Currently use medications that are potentially neuroprotective/beneficial or retinotoxic. * Are incapable of performing visual function testing (e.g., FST), with or without assistance, for reason other than poor vision. * Have any contraindication to a course of oral steroids, in the opinion of the Investigator. * Have a known history of hypersensitivity to constituents or excipients in the pharmaceutical formulation of the IMP. * Have a known or active infection of human immunodeficiency virus (HIV) or hepatitis B or C virus. * Have a known or active infection of herpes simplex virus with ocular manifestations. * Are an employee of the Sponsor or a relative of the Investigator or investigative site staff.